<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-52fc-3a32-0153-62239c5d1ef6</uuid><title>Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)</title><shortTitle>CMS135</shortTitle><emeasureid>135</emeasureid><guid>430ffc53-4122-4421-88cc-2edd8117bb3c</guid><version>5.2.000</version><nqfid extension="2907" root="2.16.840.1.113883.3.560.1"/><period calenderYear="true" uuid="40280381-3d61-56a7-013e-62367ba1298c"><startDate>00000101</startDate><stopDate>00001231</stopDate></period><steward id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</steward><developers><developer id="d041e15c-a7a0-41b8-be5b-87340ecd14bc">American Medical Association (AMA)</developer><developer id="83e9797c-adec-4446-8c35-3ffd5d981c66">PCPI(R) Foundation (PCPI[R])</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) &lt; 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge</description><copyright>Copyright 2015 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.</copyright><disclaimer>The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. &#xD;
&#xD;
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. &#xD;
&#xD;
Commercial uses of the Measures require a license agreement between the user and the PCPI(R) Foundation (PCPI[R]), the American Medical Association (AMA), American College of Cardiology (ACC) or the American Heart Association (AHA).  Neither the AMA, nor ACC, nor AHA, nor the AMA-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures. &#xD;
&#xD;
AMA and PCPI encourage use of the Measures by other health care professionals, where appropriate.&#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.&#xD;
 &#xD;
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ACC, AHA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC(R) is copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT[R]) copyright 2004-2015 International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><componentMeasures/><itemCount/><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>In the absence of contraindications, ACE inhibitors or ARBs are recommended for all patients with symptoms of heart failure and reduced left ventricular systolic function. ACE inhibitors remain the first choice for inhibition of the renin-angiotensin system in chronic heart failure, but ARBs can now be considered a reasonable alternative. Both pharmacologic agents have been shown to decrease the risk of death and hospitalization. Additional benefits of ACE inhibitors include the alleviation of symptoms and the improvement of clinical status and overall sense of well-being of patients with heart failure.</rationale><recommendations>ACE inhibitors are recommended in patients with HFrEF [heart failure with reduced ejection fraction] and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. (Class I, Level of Evidence: A) (ACCF/AHA, 2013)&#xD;
&#xD;
Treatment with an ACE inhibitor should be initiated at low doses [see excerpt from guideline table below], followed by gradual dose increments if lower doses have been well tolerated... Clinicians should attempt to use doses that have been shown to reduce the risk of cardiovascular events in clinical trials. If these target doses of an ACE inhibitor cannot be used or are poorly tolerated, intermediate doses should be used with the expectation that there are likely to be only small differences in efficacy between low and high doses. Abrupt withdrawal of treatment with an ACE inhibitor can lead to clinical deterioration and should be avoided. (ACCF/AHA, 2013)&#xD;
&#xD;
Drugs Commonly Used for Stage C HFrEF (abbreviated to align with focus of measure to include only ACE inhibitors and ARB therapy)&#xD;
Drug                       Initial Daily Dose(s)                           Maximum Doses(s)       Mean Doses Achieved in &#xD;
                                                                                                                        Clinical Trials&#xD;
ACE Inhibitors&#xD;
   Captopril              6.25 mg 3 times                               50 mg 3 times              122.7 mg/d&#xD;
   Enalapril               2.5 mg twice                                    10 to 20 mg twice         16.6 mg/d&#xD;
   Fosinopril             5 to 10 mg once                               40 mg once                  N/A&#xD;
   Lisinopril              2.5 to 5 mg once                              20 to 40 mg once          32.5 to 35.0 mg/d  &#xD;
   Perindopril           2 mg once                                        8 to 16 mg once           N/A&#xD;
   Quinapril              5 mg twice                                       20 mg twice                 N/A&#xD;
   Ramipril               1.25 to 2.5 mg once                         10 mg once                  N/A&#xD;
   Trandolapril          1 mg once                                        4 mg once                   N/A&#xD;
Angiotensin Receptor Blockers&#xD;
   Candesartan         4 to 8 mg once                                32 mg once                   24 mg/d&#xD;
   Losartan              25 to 50 mg once                             50 to 150 mg once        129 mg/d&#xD;
   Valsartan              20 to 40 mg twice                           160 mg twice                 254 mg/d&#xD;
&#xD;
ARBs are recommended in patients with HFrEF with current or prior symptoms who are ACE inhibitor intolerant, unless contraindicated, to reduce morbidity and mortality. (Class I, Level of Evidence: A)  (ACCF/AHA, 2013)&#xD;
&#xD;
ARBs are reasonable to reduce morbidity and mortality as alternatives to ACE inhibitors as first-line therapy for&#xD;
patients with HFrEF, especially for patients already taking ARBs for other indications, unless contraindicated. (Class IIa, Level of Evidence: A)  (ACCF/AHA, 2013)&#xD;
&#xD;
Addition of an ARB may be considered in persistently symptomatic patients with HFrEF who are already being&#xD;
treated with an ACE inhibitor and a beta blocker in whom an aldosterone antagonist is not indicated or tolerated. (Class IIb, Level of Evidence: A)  (ACCF/AHA, 2013)&#xD;
&#xD;
For the hospitalized patient:&#xD;
In patients with HFrEF experiencing a symptomatic exacerbation of HF requiring hospitalization during chronic&#xD;
maintenance treatment with GDMT[guideline-directed medical therapy; GDMT represents optimal medical therapy as defined by ACCF/AHA guideline-recommended therapies (primarily Class I)], it is recommended that GDMT be continued in the absence of hemodynamic instability or contraindications. (Class I, Level of Evidence: B)  (ACCF/AHA, 2013)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239. </reference></references><definitions>Prescribed-Outpatient setting: prescription given to the patient for ACE inhibitor or ARB therapy at one or more visits in the measurement period OR patient already taking ACE inhibitor or ARB therapy as documented in current medication list.&#xD;
&#xD;
Prescribed-Inpatient setting: prescription given to the patient for ACE inhibitor or ARB therapy at discharge OR ACE inhibitor or ARB therapy to be continued after discharge as documented in the discharge medication list.&#xD;
&#xD;
LVEF &lt; 40% corresponds to qualitative documentation of moderate dysfunction or severe dysfunction.</definitions><guidance>To satisfy this measure, it must be reported for all heart failure patients at least once during the measurement period if seen in the outpatient setting. If the patient has an eligible inpatient discharge during the measurement period, as defined in the measure logic, it is expected to be reported at each hospital discharge. &#xD;
&#xD;
The requirement of "Count &gt;=2 of Encounter, Performed" is to establish that the eligible professional has an existing relationship with the patient.</guidance><transmissionFormat>TBD</transmissionFormat><initialPopDescription>All patients aged 18 years and older with a diagnosis of heart failure</initialPopDescription><denominatorDescription>Equals Initial Population with a current or prior LVEF &lt; 40%</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patients who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>Documentation of medical reason(s) for not prescribing ACE inhibitor or ARB therapy (eg, hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons)&#xD;
Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy (eg, patient declined, other patient reasons)&#xD;
Documentation of system reason(s) for not prescribing ACE inhibitor or ARB therapy (eg, other system reasons)</denominatorExceptionsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex</supplementalData><qualityMeasureSet uuid="450394d4-39c6-4e6e-bbdc-33daa262716f">None</qualityMeasureSet>
<finalizedDate value="201603101413-0600"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-62367ba02987" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-62367ba12988" name="Race"/><elementRef id="40280381-3d61-56a7-013e-62367ba12989" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-62367ba1298a" name="Payer"/></supplementalDataElements><riskAdjustmentVariables/><subTreeLookUp><subTree displayName="Occurrence A of $HFEncounters135" instance="A" instanceOf="FA5C0396-6947-407E-835A-EE1BD7BDDCFF" qdmVariable="true" uuid="66FB89A1-21B4-41D2-90FA-4FF49EFA189E"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Care Services in Long-Term Residential Facility : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12996" type="qdm"/><elementRef displayName="Home Healthcare Services : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12998" type="qdm"/><elementRef displayName="Nursing Facility Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12990" type="qdm"/><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12992" type="qdm"/><elementRef displayName="Outpatient Consultation : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12994" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="799d72f0-498c-4538-846b-f54d60e9c97b" type="qdm"/><elementRef displayName="Discharge Services - Hospital Inpatient : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1298e" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" type="qdm"/></relationalOp></subTree><subTree displayName="Age 18" qdmVariable="false" uuid="F366940A-FC6E-4330-A957-ACE603AD7D5E"><functionalOp displayName="Age&gt;= 18 years at" operatorType="Greater Than or Equal To" quantity="18" type="AGE AT" unit="years"><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" type="qdm"/></functionalOp></subTree><subTree displayName="Allergy Intolerance DX overlaps Occ A HFEncounters135" qdmVariable="false" uuid="AD7F38F3-C1CD-4457-8598-E73A7C74C350"><relationalOp displayName="Overlaps" type="Overlap"><setOp displayName="Union" type="union"><elementRef displayName="ACE Inhibitor or ARB Ingredient : Medication, Allergy" id="40280381-3d61-56a7-013e-62367ba02986" type="qdm"/><elementRef displayName="Allergy to ACE Inhibitor or ARB : Diagnosis" id="6b77901b-57a9-41f8-a6fa-654ac1a40d84" type="qdm"/><elementRef displayName="ACE Inhibitor or ARB : Medication, Intolerance" id="40280381-3d61-56a7-013e-62367ba229a9" type="qdm"/><elementRef displayName="Intolerance to ACE Inhibitor or ARB : Diagnosis" id="e18e3f7f-7a7d-4171-a284-21519e734ac2" type="qdm"/><elementRef displayName="Pregnancy : Diagnosis" id="ce1572c5-371a-4a38-8a74-8031a8a510f9" type="qdm"/><elementRef displayName="Renal Failure Due to ACE Inhibitor : Diagnosis" id="418ade3c-0973-4a97-a5fe-d837e4fff797" type="qdm"/></setOp><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree><subTree displayName="Count 2 Enc during Mp" qdmVariable="false" uuid="0FCA7A8A-9E9E-4FB3-997D-40F3093E49A6"><functionalOp displayName="Count&gt;= 2 " operatorType="Greater Than or Equal To" quantity="2" type="COUNT"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Care Services in Long-Term Residential Facility : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12996" type="qdm"/><elementRef displayName="Home Healthcare Services : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12998" type="qdm"/><elementRef displayName="Nursing Facility Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12990" type="qdm"/><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12992" type="qdm"/><elementRef displayName="Outpatient Consultation : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12994" type="qdm"/><elementRef displayName="Patient Provider Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1299a" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="DX HF overlaps Occ A HFEncounters135" qdmVariable="false" uuid="04A95917-6CDD-429D-82B3-6B97FC5210AE"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="Heart Failure : Diagnosis" id="63569d9f-9ca4-4842-989f-544624bbc5de" type="qdm"/><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree><subTree displayName="Eject Frac or LVSD SBE Enc" qdmVariable="false" uuid="01352065-EBBB-4AC9-B210-2DEBBFF26D0D"><relationalOp displayName="Starts Before End Of" type="SBE"><setOp displayName="Union" type="union"><elementRef displayName="Ejection Fraction : Diagnostic Study, Performed" id="294d128a-9bd9-401b-a33d-038afa01a056" type="qdm"><attribute attrUUID="d5d247dd-bba5-466f-aa50-974f671ca2c0" comparisonValue="40" mode="Less Than" name="result" unit="%"/></elementRef><elementRef displayName="Moderate or Severe LVSD : Diagnosis" id="3d229331-f23f-4be6-b401-12606431d26b" type="qdm"/><elementRef displayName="Left Ventricular Systolic Dysfunction : Diagnosis" id="1ed4ce90-eaad-4656-b81a-8b2fbfee1f22" type="qdm"><attribute attrUUID="f2d82645-9abb-4201-bb24-6e6c7b165d80" mode="Value Set" name="severity" qdmUUID="40280381-3d61-56a7-013e-62367ba129a1"/></elementRef></setOp><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree><subTree displayName="HFEncounters135" qdmVariable="true" uuid="FA5C0396-6947-407E-835A-EE1BD7BDDCFF"><relationalOp displayName="During" type="DURING"><setOp displayName="Union" type="union"><elementRef displayName="Care Services in Long-Term Residential Facility : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12996" type="qdm"/><elementRef displayName="Home Healthcare Services : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12998" type="qdm"/><elementRef displayName="Nursing Facility Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12990" type="qdm"/><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12992" type="qdm"/><elementRef displayName="Outpatient Consultation : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12994" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="799d72f0-498c-4538-846b-f54d60e9c97b" type="qdm"/><elementRef displayName="Discharge Services - Hospital Inpatient : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1298e" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" type="qdm"/></relationalOp></subTree><subTree displayName="Hosp Inpt Enc during MP" qdmVariable="false" uuid="94B91DEA-79AC-4A4B-8439-FC12D29A3172"><relationalOp displayName="During" type="DURING"><elementRef displayName="Discharge Services - Hospital Inpatient : Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1298e" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" type="qdm"/></relationalOp></subTree><subTree displayName="Med Active overlaps OccA HFEncounters135" qdmVariable="false" uuid="1D5C5A6A-3A4F-4E07-B446-29546E744AF6"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="ACE Inhibitor or ARB : Medication, Active" id="40280381-3d61-56a7-013e-62367ba229af" type="qdm"/><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree><subTree displayName="Med Order during Occ A HFEncounters135" qdmVariable="false" uuid="32470C43-C883-4B2C-B916-2DF472B10835"><relationalOp displayName="During" type="DURING"><elementRef displayName="ACE Inhibitor or ARB : Medication, Order" id="40280381-3d61-56a7-013e-62367ba229a2" type="qdm"/><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree><subTree displayName="Med Order not done starts dur Occ A HFEncounters135" qdmVariable="false" uuid="50C94493-E83E-4674-8A8D-221CD7AFEE70"><relationalOp displayName="Starts During" type="SDU"><setOp displayName="Union" type="union"><elementRef displayName="ACE Inhibitor or ARB Ingredient : Medication, Order" id="40ed5252-ab4e-4dfd-ab57-142142839046" type="qdm"><attribute attrUUID="bb97eda5-f437-4bcb-bd2e-2868490003ab" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-62367ba229a4"/></elementRef><elementRef displayName="ACE Inhibitor or ARB Ingredient : Medication, Order" id="40ed5252-ab4e-4dfd-ab57-142142839046" type="qdm"><attribute attrUUID="ab09259a-11c3-4eed-adb5-e32cf30f938b" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-62367ba229a5"/></elementRef><elementRef displayName="ACE Inhibitor or ARB Ingredient : Medication, Order" id="40ed5252-ab4e-4dfd-ab57-142142839046" type="qdm"><attribute attrUUID="f882a0a1-62c5-414d-b911-394884b13213" mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-62367ba229a6"/></elementRef><elementRef displayName="Patient Reason for ACE Inhibitor or ARB Decline : Communication: From Patient to Provider" id="40280381-3d61-56a7-013e-62367ba229a7" type="qdm"/></setOp><subTreeRef displayName="Occurrence A of HFEncounters135" id="66FB89A1-21B4-41D2-90FA-4FF49EFA189E" type="subTree"/></relationalOp></subTree></subTreeLookUp><measureGrouping><group sequence="1"><clause displayName="Initial Population 1" type="initialPopulation" uuid="F3000871-B8FD-4F74-8892-281C250C11EA"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Age 18" id="F366940A-FC6E-4330-A957-ACE603AD7D5E" type="subTree"/><logicalOp displayName="OR" type="or"><subTreeRef displayName="Count 2 Enc during Mp" id="0FCA7A8A-9E9E-4FB3-997D-40F3093E49A6" type="subTree"/><subTreeRef displayName="Hosp Inpt Enc during MP" id="94B91DEA-79AC-4A4B-8439-FC12D29A3172" type="subTree"/></logicalOp><subTreeRef displayName="DX HF overlaps Occ A HFEncounters135" id="04A95917-6CDD-429D-82B3-6B97FC5210AE" type="subTree"/></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="C1E20830-ADFE-4D88-B979-166FA0820D5C"><logicalOp displayName="AND" type="and"><subTreeRef displayName="Eject Frac or LVSD SBE Enc" id="01352065-EBBB-4AC9-B210-2DEBBFF26D0D" type="subTree"/></logicalOp></clause><clause displayName="Denominator Exceptions 1" type="denominatorExceptions" uuid="41E08783-4358-4E0D-81BE-9616A8F58319"><logicalOp displayName="OR" type="or"><subTreeRef displayName="Med Order not done starts dur Occ A HFEncounters135" id="50C94493-E83E-4674-8A8D-221CD7AFEE70" type="subTree"/><subTreeRef displayName="Allergy Intolerance DX overlaps Occ A HFEncounters135" id="AD7F38F3-C1CD-4457-8598-E73A7C74C350" type="subTree"/></logicalOp></clause><clause displayName="Numerator 1" type="numerator" uuid="49E476F4-E8A1-48A6-B800-A8172073DBFB"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><subTreeRef displayName="Med Order during Occ A HFEncounters135" id="32470C43-C883-4B2C-B916-2DF472B10835" type="subTree"/><subTreeRef displayName="Med Active overlaps OccA HFEncounters135" id="1D5C5A6A-3A4F-4E07-B446-29546E744AF6" type="subTree"/></logicalOp></logicalOp></clause><clause displayName="denominatorExclusions" type="denominatorExclusions" uuid="a2cd75d1-24b1-4216-a241-b0b07fecde1f"><logicalOp displayName="AND" type="and"/></clause><clause displayName="numeratorExclusions" type="numeratorExclusions" uuid="804e51d0-8650-4eb6-b818-a4ac31b5675f"><logicalOp displayName="AND" type="and"/></clause><clause displayName="stratum" type="stratum" uuid="2910a81f-cc50-453c-a6fd-4540f9bae329"/></group></measureGrouping><elementLookUp><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Order" id="40280381-3d61-56a7-013e-62367ba229a2" name="ACE Inhibitor or ARB" oid="2.16.840.1.113883.3.526.3.1139" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a2" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Intolerance" id="40280381-3d61-56a7-013e-62367ba229a9" name="ACE Inhibitor or ARB" oid="2.16.840.1.113883.3.526.3.1139" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a9" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Active" id="40280381-3d61-56a7-013e-62367ba229af" name="ACE Inhibitor or ARB" oid="2.16.840.1.113883.3.526.3.1139" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229af" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Allergy" id="40280381-3d61-56a7-013e-62367ba02986" name="ACE Inhibitor or ARB Ingredient" oid="2.16.840.1.113883.3.526.3.1489" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba02986" version="1"/><qdm datatype="Medication, Order" id="40ed5252-ab4e-4dfd-ab57-142142839046" name="ACE Inhibitor or ARB Ingredient" oid="2.16.840.1.113883.3.526.3.1489" suppDataElement="false" taxonomy="Grouping" uuid="40ed5252-ab4e-4dfd-ab57-142142839046" version="1.0"/><qdm datatype="Diagnosis" id="6b77901b-57a9-41f8-a6fa-654ac1a40d84" name="Allergy to ACE Inhibitor or ARB" oid="2.16.840.1.113883.3.526.3.1211" suppDataElement="false" taxonomy="Grouping" uuid="6b77901b-57a9-41f8-a6fa-654ac1a40d84" version="1.0"/><qdm datatype="Patient Characteristic Birthdate" id="56dc2df6-7d59-488d-a2ba-004fe94bff7a" name="Birthdate" oid="21112-8" suppDataElement="false" taxonomy="SNOMED-CT" uuid="56dc2df6-7d59-488d-a2ba-004fe94bff7a" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12996" name="Care Services in Long-Term Residential Facility" oid="2.16.840.1.113883.3.464.1003.101.12.1014" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba12996" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1298e" name="Discharge Services - Hospital Inpatient" oid="2.16.840.1.113883.3.464.1003.101.12.1007" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba1298e" version="1"/><qdm datatype="Diagnostic Study, Performed" id="294d128a-9bd9-401b-a33d-038afa01a056" name="Ejection Fraction" oid="2.16.840.1.113883.3.526.3.1134" suppDataElement="false" taxonomy="Grouping" uuid="294d128a-9bd9-401b-a33d-038afa01a056" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-62367ba12989" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-62367ba12989" version="1"/><qdm datatype="Patient Characteristic Expired" id="b704ad37-9ff1-4281-a2bc-a29007d8c5a0" name="Expired" oid="419099009" suppDataElement="false" taxonomy="SNOMED-CT" uuid="b704ad37-9ff1-4281-a2bc-a29007d8c5a0" version="1.0"/><qdm datatype="Encounter, Performed" id="799d72f0-498c-4538-846b-f54d60e9c97b" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="799d72f0-498c-4538-846b-f54d60e9c97b" version="1.0"/><qdm datatype="Diagnosis" id="63569d9f-9ca4-4842-989f-544624bbc5de" name="Heart Failure" oid="2.16.840.1.113883.3.526.3.376" suppDataElement="false" taxonomy="Grouping" uuid="63569d9f-9ca4-4842-989f-544624bbc5de" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12998" name="Home Healthcare Services" oid="2.16.840.1.113883.3.464.1003.101.12.1016" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba12998" version="1"/><qdm datatype="Diagnosis" id="e18e3f7f-7a7d-4171-a284-21519e734ac2" name="Intolerance to ACE Inhibitor or ARB" oid="2.16.840.1.113883.3.526.3.1212" suppDataElement="false" taxonomy="Grouping" uuid="e18e3f7f-7a7d-4171-a284-21519e734ac2" version="1.0"/><qdm datatype="Diagnosis" id="1ed4ce90-eaad-4656-b81a-8b2fbfee1f22" name="Left Ventricular Systolic Dysfunction" oid="2.16.840.1.113883.3.526.3.1091" suppDataElement="false" taxonomy="Grouping" uuid="1ed4ce90-eaad-4656-b81a-8b2fbfee1f22" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-62367ba1298c" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-62367ba1298c" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-62367ba229a4" name="Medical Reason" oid="2.16.840.1.113883.3.526.3.1007" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a4" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-62367ba129a1" name="Moderate or Severe" oid="2.16.840.1.113883.3.526.3.1092" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba129a1" version="1"/><qdm datatype="Diagnosis" id="3d229331-f23f-4be6-b401-12606431d26b" name="Moderate or Severe LVSD" oid="2.16.840.1.113883.3.526.3.1090" suppDataElement="false" taxonomy="Grouping" uuid="3d229331-f23f-4be6-b401-12606431d26b" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12990" name="Nursing Facility Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1012" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba12990" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12992" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba12992" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-62367ba02987" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="AdministrativeGender" uuid="40280381-3d61-56a7-013e-62367ba02987" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba12994" name="Outpatient Consultation" oid="2.16.840.1.113883.3.464.1003.101.12.1008" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba12994" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62367ba1299a" name="Patient Provider Interaction" oid="2.16.840.1.113883.3.526.3.1012" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba1299a" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-62367ba229a5" name="Patient Reason" oid="2.16.840.1.113883.3.526.3.1008" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a5" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Communication: From Patient to Provider" id="40280381-3d61-56a7-013e-62367ba229a7" name="Patient Reason for ACE Inhibitor or ARB Decline" oid="2.16.840.1.113883.3.526.3.1140" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a7" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-62367ba1298a" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="SOP" uuid="40280381-3d61-56a7-013e-62367ba1298a" version="1"/><qdm datatype="Diagnosis" id="ce1572c5-371a-4a38-8a74-8031a8a510f9" name="Pregnancy" oid="2.16.840.1.113883.3.526.3.378" suppDataElement="false" taxonomy="Grouping" uuid="ce1572c5-371a-4a38-8a74-8031a8a510f9" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-62367ba12988" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-62367ba12988" version="1"/><qdm datatype="Diagnosis" id="418ade3c-0973-4a97-a5fe-d837e4fff797" name="Renal Failure Due to ACE Inhibitor" oid="2.16.840.1.113883.3.526.3.1151" suppDataElement="false" taxonomy="Grouping" uuid="418ade3c-0973-4a97-a5fe-d837e4fff797" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-62367ba229a6" name="System Reason" oid="2.16.840.1.113883.3.526.3.1009" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62367ba229a6" version="1"/></elementLookUp></measure>